Education
About Us
Working with TipRanks
Follow Us
LadRx (LADX)
OTHER OTC:LADX
LADX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $2.80
Previous CloseN/A
Volume2.00
Average Volume (3M)2.70K
Market Cap
$717.88K
Enterprise Value-$866.07K
Total Cash (Recent Filing)$206.95K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding495,092
10 Day Avg. Volume182
30 Day Avg. Volume2,704
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit618.18
Enterprise Value/Ebitda0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
LadRx News
LADX FAQ
What was LadRx’s price range in the past 12 months?
LadRx lowest stock price was $0.46 and its highest was $2.80 in the past 12 months.
What is LadRx’s market cap?
LadRx’s market cap is $717.88K.
When is LadRx’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LadRx’s earnings last quarter?
Currently, no data Available
Is LadRx overvalued?
According to Wall Street analysts LadRx’s price is currently Overvalued.
Does LadRx pay dividends?
LadRx does not currently pay dividends.
What is LadRx’s EPS estimate?
LadRx’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LadRx have?
LadRx has 495,092 shares outstanding.
What happened to LadRx’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LadRx?
Currently, no hedge funds are holding shares in LADX
Company Description
LadRx
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Ownership Overview
79.21%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---